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ABSTRACT
For patients with rheumatoid arthritis (RA), remission 
can be achieved with tight control of infl ammation and 
early use of disease modifying agents. The importance of 
remission as an outcome has been recently highlighted by 
European League Against Rheumatism recommendations. 
However, remission when defi ned by clinical remission 
criteria (disease activity score, simplifi ed disease activity 
index, etc) does not always equate to the complete 
absence of infl ammation as measured by new sensitive 
imaging techniques such as ultrasound (US) .  There 
is evidence that imaging synovitis is frequently found 
in these patients and associated with adverse clinical 
and functional outcomes. This article reviews the data 
regarding remission, ultrasound imaging and outcomes 
in patients with RA to provide the background to a 
consensus statement from an international collaboration 
of ultrasonographers and rheumatologists who have 
recently formed a research network - the Targeted 
Ultrasound Initiative (TUI) group. The statement proposes 
that targeting therapy to PD activity provides superior 
outcomes compared with treating to clinical targets alone 
and introduces the rationale for a new randomised trial 
using targeted ultrasound in RA.
The management of rheumatoid arthritis (RA) 
has changed dramatically over the last few years 
due to the impact of improved strategies and new 
therapies. Early diagnosis and effective treatment 
of RA have been shown to improve symptom con-
trol, long-term structural damage and functional 
status.1 Rapid escalation of disease modifying anti-
rheumatic drugs (DMARDs) and the early use of 
biologic agents have been central in increasing the 
rates of remission by rapidly controlling infl amma-
tion.2–9 European League Against Rheumatism rec-
ommendations10 reinforced by the treat-to-target 
approach11 have set remission as the primary treat-
ment goal for RA in everyday clinical practice.
HOW IS CLINICAL REMISSION DEFINED?
For many years, the American College of 
Rheumatology (ACR) preliminary criteria for clini-
cal remission have been the dominant instrument 
for measuring remission.12 These were followed 
by remission criteria derived from disease activity 
score (DAS) and DAS28.13 14 However, both criteria 
relied on surrogates for infl ammation with cut-off 
values representing remission.
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These surrogates have limitations which include 
the potential underestimation of disease activity 
in the presence of true joint synovitis15–22 either 
due to the insensitivity of clinical assessment or 
the lack of acute phase elevation. Conversely, such 
measures may overestimate disease activity (sub-
jective parameters such as tender joint counts (TJC) 
depend on a patient’s pain threshold and coexistent 
conditions, eg, osteoarthritis and fi bromyalgia). 
Additionally, there is the diffi culty of assessing 
swollen joint counts (SJCs) in established disease 
because of deformity and residual fi brous tissue, 
neither of which corresponds to real infl ammatory 
activity. More recent composite criteria, including 
the simplifi ed disease activity index (SDAI) and 
clinical disease activity index, still rely on clinical 
criteria with the above limitations.23 24 Each is sub-
tly different with respect to its core components, 
that is, the calculation method used or cut-off level 
that is applied. The alternative criteria are more 
stringent than DAS28, but radiographic progression 
continues in some patients independent of which 
criteria are used.22 25 26 Additionally, these criteria 
were developed for clinical trial purposes and are 
effective at a ‘group level’ for evaluating respon-
siveness and outcomes. However at a ‘patient 
level’, due to the previously discussed limitations, 
clinical remission criteria are unable to accurately 
defi ne an absence of infl ammation and therefore 
may not represent suitable targets when aiming for 
tight control. There is general agreement these cri-
teria may, in fact, be defi ning low disease activity 
state rather than true remission.
HOW SHOULD REMISSION BE DEFINED AND 
DETERMINED?
Because of these limitations, the ACR and European 
League Against Rheumatism, together with 
OMERACT (Outcome Measures in Rheumatology), 
have recently worked to redefi ne remission in RA.27 
Tasked with developing a strict defi nition of remis-
sion at a minimum, including TJC and SJC and an 
acute phase reactant, this exercise resulted in two 
defi nitions of remission, one for clinical trials with 
C reactive protein and another for clinical practice 
without:
▶ when a patient’s scores on the following mea-
sures are all ≤1: TJC, SJC, C reactive protein and 
patient global assessment or
▶ when a patient’s score on the SDAI is ≤3.3.
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While the standardisation is a major advance, these criteria 
still depend on the assumption that clinical assessment vari-
ables are an accurate refl ection of the presence and degree of 
synovitis and thus can determine signs of synovitis, that is, 
infl ammation.
With increasing evidence that synovitis, the primary site 
of pathology in RA, is closely linked to the development of 
radiographic structural damage,28 it is logical that a defi nition 
of remission should relate to the near or complete abolition of 
synovitis. Therefore, the use of imaging modalities to determine 
infl ammation may be considered necessary to determine future 
management decisions.
IMAGING AND REMISSION
Imaging techniques such as ultrasound and MRI have the 
capability to directly visualise both synovitis and bone dam-
age. Both have recently become more readily accessible to clini-
cians and applied for use in RA. Each has their own advantages 
and disadvantages, although on a practical level, ultrasound 
is less expensive, easily repeatable, able to be delivered at the 
point of care and can be more feasibly used to assess mul-
tiple joint areas at one sitting. The relevant MR papers are 
referenced.28–34
Ultrasound can be used to assess two aspects of synovitis: 
its morphology and quantity using grey scale (GS) and synovial 
vascularity as measured by colour or power Doppler (PD). It is 
the latter component that has attracted particular attention as 
this has been shown to better correlate with infl ammatory activ-
ity than GS alone.35
The aim of this paper is to refl ect on recent published 
data relating to the utility of ultrasound in defi ning and 
determining remission in RA patients and to present the outline 
of a newly planned study attempting to determine the 
signifi cance of subclinical synovitis. A summary of the 
key papers relating to ultrasound and remission is given in 
table 1.
Table 1 Ultrasound and remission: the evidence base
Author Year
Number of 
patients Treatment
Defi nition 
of clinical 
remission for 
inclusion into 
study Joints scanned
Defi nition 
of ‘imaging 
remission’ Time to scan
Brown et al 15 2006 107, late DD 
median 7 years2–38
DMARD As defi ned by 
treating 
rheumatologist
Five joints; dominant 
wrist and MCPJ2–5
Used a 
semiquantitative 
score; did not defi ne 
imaging remission
30 Min
Wakefi eld et al 36 2007 10, early DD median 6 
m (3–11 months)
Anti-TNF DAS28 <2.6; NB: 
patients had active 
disease at inclusion
42 Joints: shoulders, 
elbows, wrists, 
MCPJ, PIPJ, knees, 
ankles, MTPJ
Semiquantitative 
score for GS and 
PD; remission defi ned 
as absence of GS 
and PD
50 Min
Saleem et al 16 2009 100, late DD; 
median 120 months 
(72–183)
50 DMARD, 50 
anti-TNF
DAS28<2.6 Five joints: 
dominant wrist and 
MCPJ2–5
Semiquantitative 
score for GS and 
PD; remission 
defi ned as absence 
of GS and PD
30 Min
Balsa et al 37 2010 97, late (mean 
DD 5.9 years)
DMARD, biologic As defi ned by 
treating 
rheumatologist
42 Joints: shoulders, 
elbows, wrists, 
MCPJ, PIPJ, knees, 
ankles, TNJ and 
MTPJ
Semiquantitative 
for GS and PD; 
remission defi ned as 
an absence of joints 
with a PD signal
45 Min (including 
documentation)
Scirè et al 38 2009 106, early DMARD DAS<1.6 44 Joints: shoulders, 
elbows, wrists, MCPJ, 
PIPJ, SCJ, ACJ, knee, 
ankle and MTP
Semiquantitative 
score for PD and 
GS; did not defi ne 
imaging remission; 
calculated a 
summative score
60 Min
Peluso et al 39 2011 94 (48 early: 6.9 
months±3) and 
46 late: 118.9 
months±71.7)
Early: DMARD±anti 
%) Late: All 
DMARD±anti-TNF
DAS<1.6 10 Joints (12 joint 
areas): bilateral 
MCPJ 2–3, PIPJ 2–3, 
wrist (two regions)
Used 3 defi nitions: 
active synovitis 
(SH and PD), US 
remission: no SH 
or PD; inactive 
synovitis: SH but 
no PD
Not documented
Saleem et al 40 2010 47 (27 early: DD 
19 months, 20 late: 
DD 120 months)
All DMARD and 
anti-TNF
DAS28<2.6 Five joints: dominant 
wrist and MCPJ2–5
Semiquantitative 
score for GS and 
PD; remission 
defi ned as absence 
of GS and PD
30 Min
Saleem et al 48 2011 128, late; DD 
8 years (5–13 years)
DMARD and TNF 
blocker
DAS28<2.6 Five joints; dominant 
wrist and MCPJ2–5
Semiquantitative 
score; imaging 
remission – 1. no 
GS or PD; 2. low 
disease activity 
(GS≤1) and PD=0; 3. 
PD=0; 4. PD≤1
30 Min
DAS, disease activity score; DMARD, disease modifying antirheumatic drugs; GS, grey scale; MCPJ, metacarpophalangeal joint; PD, power Doppler; TNF, tumour necrosis factor; 
US, ultrasound, DD, disease duration; PIPJ, proximal inter-phalangeal joint; TNJ, talo-navicular joint; ACJ, acromio-clavicular joint; MTP, metatarsophalangeal joint; SH, synovial 
hypertrophy; NB, Nota Bene, note.
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HOW DO CLINICAL CRITERIA COMPARE WITH ULTRASOUND 
CRITERIA?
The fi rst insight into a discrepancy between ultrasound fi ndings 
and clinical composite indices of remission was from a study 
by Brown et al.15 The dominant wrists and 2nd–5th metacarpo-
phalangeal joints of 102 patients using conventional DMARDs 
deemed in clinical remission (as determined by the treating rheu-
matologists) for least 6 months were scanned using both ultra-
sound and MRI. It demonstrated that, in at least one scanned 
joint, 74% and 43% of patients had GS or PD synovitis, respec-
tively. This compared with the very small number of patients 
who had clinical synovitis. MRI confi rmed the ultrasound fi nd-
ings but also highlighted an even higher number of patients 
with synovitis. More recent studies using ultrasound in different 
RA groups and scanning different sets of joints have confi rmed 
similar fi ndings.16 36–39
In a subsequent study of 128 patients with RA (DAS<2.6; 
median <1.7) who were taking either DMARD or an antitumour 
necrosis factor (TNF) agent, ultrasound was performed on the 
dominant wrist and metacarpophalangeal joint 2–5. In patients 
fulfi lling DAS28, modifi ed ACR or SDAI remission criteria, 
moderate or severe PD activity was present in 21%, 15% and 
19%, respectively. Although more stringent criteria reduced the 
number of swollen or tender joints, the number of joints with 
PD did not change.16
DOES DISEASE DURATION AFFECT THE CHANCE OF 
IMAGING REMISSION?
It is accepted that starting treatment early in patients with RA 
results in higher remission rates, a higher chance of sustained 
remission after stopping TNFα inhibitors and less radiographic 
progression when compared with patients who have received 
delayed treatment.40–46 Comparisons of imaging assessments in 
patients with early and late disease have also been published but 
in non-comparable cohorts.8 40
Peluso et al aimed to defi ne how many patients in DAS (<1.6) 
remission reached ultrasound remission in a cohort of patients 
with early RA (ERA) compared with longstanding RA (LSRA).8 
ERA patients in remission had lower PD scores and were more 
likely to have absent imaging synovitis (no GS and no PD) 
(43.7%) when compared with patients with LSRA (17.4%).
Saleem et al compared the ultrasound fi ndings in DAS28 remis-
sion patients according to the timing of therapy with anti-TNF 
therapy.40 Patients who received combination anti-TNF therapy 
as ‘fi rst-line’ were compared with patients who received delayed 
treatment after failing DMARD and fulfi lling National Institute 
for Health and Clinical Excellence criteria. GS synovial hypertro-
phy was very common in all patients. However, patients from 
the early treatment group had signifi cantly lower GS synovial 
hypertrophy scores when compared with patients from the 
late group (median total score 5 vs 12; p=0.02). Thirty-fi ve per-
cent of patients from the early group and 45% of patients from 
the delayed treatment group had PD activity (PD>0) (p=0.63). 
No differences in PD score were noted.
The level of GS synovitis correlates with disease duration, 
probably refl ecting the level of previous infl ammation and sub-
sequent fi brotic change.16 In contrast, the presence of PD is inde-
pendent of disease duration and therefore appears to be a better 
marker of infl ammation at any given time point.22
IS THE ABSENCE OF IMAGING SYNOVITIS IMPORTANT?
Persistent infl ammation in RA is known to lead to cartilage and 
bone destruction28 and PD is a refl ection of infl ammation.35 
Thus, it is possible that the key to long-term disease control 
could be to achieve prompt and substantial control of infl am-
mation measured at the imaging level. The evidence for this will 
now be discussed.
The impact of PD activity in patients in remission treated with 
DMARDs has been determined by evaluated studies. Evidence 
has shown that PD predicts radiographic progression, disease 
fl are and persistence of disease in patients with RA with low 
disease activity/remission.38 39 47 In at least one paper, PD activ-
ity has been shown to be the best predictor of subsequent joint 
damage in the affected joint, with an OR of 12. As multivari-
ate analyses were not included, an independent predictive value 
was not defi nitively established. Thus, PD can predict radiologi-
cal progression in certain patients but is it clinically important? 
One indication of relevance would be a fl are of disease, defi ned 
as the need to increase therapy. One study found at least 50% 
patients in remission had a fl are within 2 years.26
Saleem et al recently studied 93 patients deemed in sta-
ble DMARDs remission over a 12-month period of whom 
26 patients had a fl are over the period.47 Interestingly, the pres-
ence of PD was found to be the strongest independent predictor 
of fl are (OR 4.08 (1.26–13.19); p=0.014) as none of the routine 
clinical indices of remission were predictive. The potential value 
of PD was also highlighted by Peluso et al 39 who noted that 
only 20% of patients without PD had a fl are over 12 months 
compared with 47.1% who did. Similarly, Scirè et al noted that 
PD was a better predictor of short-term relapse compared with 
clinical tools (DAS and SJC) with an OR of 12.8.38
HOW SHOULD ULTRASOUND SYNOVITIS BE DEFINED?
Though there is strong evidence that clinical measures do not 
refl ect a true absence of synovitis and that ultrasound synovi-
tis is associated with worse clinical and radiographic outcomes 
in patients, questions remain as to whether aiming for imaging 
remission is achievable and how it should be defi ned. There are 
a number of considerations: for example, which joints should be 
scanned, which scoring systems should be used (and what cut-offs 
applied) and likelihood of concurrent OA (osteoarthritis). The stud-
ies previously described have involved scanning between 5 and 
42 joints; however, for ultrasound to be a feasible imaging modal-
ity, with respect to practicality, identifying the minimal number 
of joints scanned (that still provide the maximum amount of 
clinically and patient-relevant information) is crucial.
The majority of remission studies have set stringent defi ni-
tions of remission (ie, absent PD and GS synovial hypertro-
phy). However, a more feasible defi nition may include only PD 
activity; however, the minimal accepted level of PD activity is 
unknown, but median PD scores of 0.5 based on scanning fi ve 
hand joints using 0–3 semiquantitative score has been shown to 
be associated with adverse radiographic and clinical outcomes, 
respectively.22
TARGETED ULTRASOUND IN RA (TURA) 
There is now a compelling argument to suggest that the addi-
tion of an ultrasound assessment to the management of patients 
with infl ammatory arthritis is likely to improve the prediction 
of clinical outcomes. Treating to clinical targets, as described, 
has previously been shown to improve outcome. However, it 
remains to be determined whether targeting therapy to imag-
ing measures provides superior outcomes compared with 
treating to clinical targets alone. It is against this background 
that an international collaboration of ultrasonographers and 
rheumatologists recently formed an educational and research 
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network, the targeted ultrasound initiative (TUI) group, in 
order to undertake an international study in eight countries, the 
Targeted Ultrasound in RA (TURA) study, that could determine 
the added value of ultrasound to state-of-the-art management of 
RA and thus provide a key missing piece of the jigsaw puzzle. 
This could lead to a paradigm shift in the management of RA 
and especially if supported by the results of two other ongoing 
ultrasound based interventional RCTs (Randomised Controlled 
Trial) in ERA (NCT 00920478 and NCT 01205854).
The TUI group has devised a pragmatic study, (TURA), where 
patients with RA in sustained clinical remission are randomised 
to undergo an ultrasound assessment in order to determine the 
presence of PD. In those patients where an abnormal level of 
PD is detected, the DMARD treatment will be increased even 
if the clinical measures demonstrate remission. In those not 
having an ultrasound, treatment changes will be based on clini-
cal outcome measures alone. It is intended that the study will 
be an important way forward in understanding the signifi cance 
of subclinical synovitis especially PD and whether suppres-
sion of these will have a signifi cant impact on future structural 
and functional outcomes. In addition, the minimum clinically 
important level of ultrasound abnormality will be elucidated.
The aims of this study are: fi rst, if using ultrasound as the 
target in a study is a feasible approach; second, if by targeting 
PD, joint infl ammation will be reduced and, fi nally, in patients 
in whom PD is reduced, if outcomes will be improved compared 
with clinically similar patients with persistent PD. The second-
ary aims include determination of the optimal number of joints 
to be scanned.
The overarching goal of the study is to determine whether 
the application of ultrasound in clinical practice infl uences key 
outcomes. Thus, if positive, the TURA study will provide the 
evidence to support the routine use of ultrasound in the man-
agement RA, a fi nding that could have major implications for 
the rheumatology community.
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